Slingshot members are tracking this event:

Allergan Announces U.S. Availability of VRAYLAR (cariprazine) for Treatment of Bipolar Mania and Schizophrenia in Adults

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details The safety and efficacy of VRAYLAR was studied in a clinical trial program which included more than 2,700 adult patients suffering from schizophrenia or bipolar mania. VRAYLAR will be commercially available in 30 count bottles in 1.5mg, 3mg, 4.5mg and 6mg and a 7 count mixed blister pack (one 1.5mg and six 3mg tablets).

Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 16, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Vraylar, Cariprazine, Bipolar Mania, Schizophrenia